Ovid Therapeutics
138 articles about Ovid Therapeutics
-
Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures
3/8/2023
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced the publication of multiple preclinical studies of OV350 in Cell Reports Medicine.
-
Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference
2/28/2023
Ovid Therapeutics Inc. (NASDAQ: OVID) today announced that management will participant in a panel titled “Orphan Epilepsies” at the Cowen 43rd Annual Healthcare Conference in Boston, Massachusetts on March 6, 2023, at 12:50 p.m. ET.
-
Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments
2/8/2023
Ovid Therapeutics Inc. is expanding its medical and development team with the respective appointments of industry veterans, Manoj Malhotra, M.D., as its Chief Medical Officer and Toshiya Nishi, D.V.M., as its Head of Epilepsy Research.
-
Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 TrialA Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options
1/5/2023
Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, dosed healthy volunteers with OV329 in late December 2022, as part of a Phase 1 study.
-
Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)
12/2/2022
Ovid Therapeutics Inc. (NASDAQ: OVID) today announced that preclinical data supporting its OV329 and OV350 programs in epilepsy and treatment-resistant seizures will be presented at the 2022 American Epilepsy Society (AES) Annual Meeting, taking place December 2-6 in Nashville, Tennessee.
-
Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference
9/27/2022
Ovid Therapeutics Inc. today announced that management will present at the Ladenburg Thalmann 2022 Healthcare Conference in New York, New York on Thursday, September 29, 2022, at 9:00 a.m. ET.
-
Industry observers say the Inflation Reduction Act of 2022 could affect the direction of research, and some fear it may lead to further government forays into price control.
-
Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
9/7/2022
Ovid Therapeutics Inc. announced that management will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York, New York on Monday, September 12, 2022, at 12:00 p.m. ET.
-
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
8/9/2022
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today reported financial results and corporate highlights for the second quarter ended June 30, 2022.
-
Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference
6/6/2022
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, presented data at the 2022 Epilepsy Foundation Pipeline Conference.
-
Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
5/10/2022
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today reported financial results and corporate highlights for the first quarter ended March 31, 2022.
-
Ovid Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
4/8/2022
Ovid Therapeutics Inc. today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 12:45 p.m. ET.
-
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results
3/15/2022
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021.
-
Ovid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference
3/4/2022
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people affected by epilepsies and rare neurological disorders, today announced that management will participate virtually in the “Orphan Neuro and Neuromuscular” panel discussion at the Cowen 42nd Annual Health Care Conference.
-
On Wednesday, Massachusetts-based ConforMIS said it was suspending all distribution of its orthopedic medical devices to Russia and any Russian-based entities.
-
On Sunday, Boehringer Ingelheim tweeted a message of support for Ukraine, and announced it was standing in solidarity with the embattled Eastern-European country.
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
Healx and Ovid Therapeutics to Enter Strategic Partnership
2/8/2022
Ovid Therapeutics announced that Healx has secured from Ovid an exclusive option to license rights to develop and commercialize gaboxadol. Under the agreement, Healx plans to investigate the compound as part of a potential combination therapy for Fragile X syndrome, as well as a treatment for other indications.
-
New York-based Ovid Therapeutics and Healx have entered a strategic partnership to investigate the compound gaboxadol to treat Fragile X Syndrome (FXS).
-
Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators
1/3/2022
Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid’s franchise of potential first-in-class anti-epileptic therapies.